Regular ArticleMolecular Cloning, Expression, and Characterization of CYP2D17 from Cynomolgus Monkey Liver☆
References (35)
- et al.
Biochem. Biophys. Acta
(1994) - et al.
Biochem. Biophys. Acta
(1989) - et al.
Biochim. Biophys. Acta
(1998) - et al.
Biochim. Biophys. Acta
(1992) - et al.
Biochim. Biophys. Acta
(1992) - et al.
Arch. Biochem. Biophys.
(1997) - et al.
Biochem. Pharmacol.
(1998) - et al.
Biochem. Pharmacol.
(1991) J. Biol. Chem.
(1977)- et al.
J. Biol. Chem.
(1964)
Anal. Biochem.
Biochem. Pharmacol.
Biochem. Pharmacol.
J. Biol. Chem.
Pharmacogenetics
Xenobiotica
Crit. Rev. Toxicol.
Cited by (38)
Polymorphic cytochromes P450 in non-human primates
2022, Advances in PharmacologyCitation Excerpt :Cynomolgus CYP2D6 and CYP2D8 are highly homologous to human CYP2D6 (Table 1). Cynomolgus CYP2D6 and CYP2D8 are expressed predominantly in liver at the mRNA level and catalyze dextromethorphan O-deethylation and bufuralol 1′-hydroxylation, similar to human CYP2D6 (Mankowski et al., 1999; Uno, Uehara, Kohara, Murayama, & Yamazaki, 2010). Both cynomolgus CYP2D enzymes catalyze dextromethorphan N-demethylation more efficiently than human CYP2D6 does (Uno et al., 2010).
Pyronaridine tetraphosphate efficacy against Ebola virus infection in guinea pig
2020, Antiviral ResearchCitation Excerpt :The accumulated in vitro metabolic data indicates that the guinea pig may be a suboptimal model to predict the efficacy of these compounds to combat EBOV. This could be due to differences in EBOV mechanism and drug metabolism (e.g. species differences in the metabolic enzymes involved (Mankowski et al., 1999; Shimada et al., 1997)). Our combined in vitro and in vivo studies with pyronaridine demonstrate its potential utility for repurposing as an antiviral against different strains of EBOV and MARV.
Expression profile of hepatic genes in cynomolgus macaques bred in Cambodia, China, and Indonesia: Implications for cytochrome P450 genes
2012, Drug Metabolism and PharmacokineticsRegio- and stereoselective oxidation of propranolol enantiomers by human CYP2D6, cynomolgus monkey CYP2D17 and marmoset CYP2D19
2011, Chemico-Biological InteractionsCitation Excerpt :CYP2D6 shows extensive genetic polymorphism, and some 80 allelic variants have been reported to date [6], resulting in variation in drug-response phenotypes such as poor, intermediate, extensive and super-extensive metabolizers [4]. Cynomolgus monkeys and marmosets also have many CYPs [2] including CYP2D enzymes; CYP2D17 for cynomolgus monkeys [7] and CYP2D19 [8] and CYP2D30 [9] for marmosets. Propranolol (PL) is a classical adrenoceptor blocking agent used clinically to treat arrhythmia and hypertension.
Regional distribution of drug-metabolizing enzyme activities in the liver and small intestine of cynomolgus monkeys
2011, Drug Metabolism and PharmacokineticsComparative study of the oxidation of propranolol enantiomers in hepatic and small intestinal microsomes from cynomolgus and marmoset monkeys
2010, Chemico-Biological Interactions
- ☆
The nucleotide sequence encoding CYP2D17 appears in GenBank under Accession No. U38218, and the subfamily designation was assigned by David Nelson of the CYP Nomenclature Committee.
- 2
Present address: Lilly Research Labs, Lilly Corporate Center, Indianapolis, IN 46285.
- 3
Present address: Bristol Myers Squibb, 5 Research Parkway, Wallingford, CT 06942.